Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 382K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 23K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 19K
12: R1 Document and Entity Information HTML 39K
13: R2 Consolidated Balance Sheets HTML 125K
14: R3 Consolidated Balance Sheets (Parenthetical) HTML 42K
15: R4 Consolidated Statements of Income (Unaudited) HTML 80K
16: R5 Consolidated Statements of Comprehensive Income HTML 44K
(Unaudited)
17: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 117K
18: R7 Basis of Presentation HTML 24K
19: R8 Zedge Spin-Off HTML 31K
20: R9 Investment in Cornerstone Pharmaceuticals, Inc. HTML 30K
21: R10 Marketable Securities HTML 59K
22: R11 Fair Value Measurements HTML 40K
23: R12 Derivative Instruments HTML 35K
24: R13 Equity HTML 47K
25: R14 Earnings Per Share HTML 36K
26: R15 Revolving Credit Loan Payable HTML 24K
27: R16 Accrued Severance Expense HTML 21K
28: R17 Accumulated Other Comprehensive Loss HTML 32K
29: R18 Business Segment Information HTML 51K
30: R19 Commitments and Contingencies HTML 41K
31: R20 Other (Expense) Income, Net HTML 28K
32: R21 Income Taxes HTML 23K
33: R22 Recently Issued Accounting Standard Not Yet HTML 32K
Adopted
34: R23 Zedge Spin-Off (Tables) HTML 26K
35: R24 Marketable Securities (Tables) HTML 87K
36: R25 Fair Value Measurements (Tables) HTML 36K
37: R26 Derivative Instruments (Tables) HTML 25K
38: R27 Equity (Tables) HTML 40K
39: R28 Earnings Per Share (Tables) HTML 45K
40: R29 Accumulated Other Comprehensive Loss (Tables) HTML 27K
41: R30 Business Segment Information (Tables) HTML 60K
42: R31 Commitments and Contingencies (Tables) HTML 28K
43: R32 Other (Expense) Income, Net (Tables) HTML 31K
44: R33 Zedge Spin-Off (Details) HTML 27K
45: R34 Investment in Cornerstone Pharmaceuticals, Inc. HTML 87K
(Details)
46: R35 Marketable Securities (Details) HTML 64K
47: R36 Marketable Securities (Details 1) HTML 34K
48: R37 Marketable Securities (Details 2) HTML 44K
49: R38 Marketable Securities (Details Textual) HTML 38K
50: R39 Fair Value Measurements (Details) HTML 30K
51: R40 Fair Value Measurements (Details Textual) HTML 22K
52: R41 Derivative Instruments (Details) HTML 21K
53: R42 Equity (Details) HTML 62K
54: R43 Equity (Details Textual) HTML 60K
55: R44 Earnings Per Share (Details) HTML 33K
56: R45 Earnings Per Share (Details 1) HTML 22K
57: R46 Revolving Credit Loan Payable (Details) HTML 46K
58: R47 Accrued Severance Expense (Details) HTML 26K
59: R48 Accumulated Other Comprehensive Loss (Details) HTML 48K
60: R49 Business Segment Information (Details) HTML 42K
61: R50 Business Segment Information (Details Textual) HTML 20K
62: R51 Commitments and Contingencies (Details) HTML 28K
63: R52 Commitments and Contingencies (Details Textual) HTML 40K
64: R53 Other (Expense) Income, Net (Details) HTML 33K
65: R54 Income Taxes (Details) HTML 24K
67: XML IDEA XML File -- Filing Summary XML 117K
66: EXCEL IDEA Workbook of Financial Reports XLSX 61K
6: EX-101.INS XBRL Instance -- idt-20170131 XML 1.04M
8: EX-101.CAL XBRL Calculations -- idt-20170131_cal XML 137K
9: EX-101.DEF XBRL Definitions -- idt-20170131_def XML 382K
10: EX-101.LAB XBRL Labels -- idt-20170131_lab XML 931K
11: EX-101.PRE XBRL Presentations -- idt-20170131_pre XML 600K
7: EX-101.SCH XBRL Schema -- idt-20170131 XSD 127K
68: ZIP XBRL Zipped Folder -- 0001213900-17-002245-xbrl Zip 100K
Filing Submission 0001213900-17-002245 – SGML Text
To view the SGML, please refresh this page.
↑Top
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help —
Tue., Apr. 30, 11:00:36.2am ET 
